Results 111 to 120 of about 4,268 (199)

Fetal Defects in Mice Treated with Integrase Strand Transfer Inhibitors: Comparison of Dolutegravir, Raltegravir, Bictegravir and Cabotegravir

Background: Integrase strand transfer inhibitors (INSTIs) are preferred for treatment of HIV. However, safety data in pregnancy are limited for newer INSTIs.
Nguyen, Jessica, Yee, Audrey, Sanghvi, Tanvi, Copp, Andrew J, Serghides, Lena, Mohan, Haneesha, Tejada, Oscar, Jao, Jennifer, Greene, Nicholas DE, Sled, John G, Laurette, Evelyn Yukino   +10 more
core   +1 more source

Patient-Reported Outcomes with Long-Acting Cabotegravir and Rilpivirine in People Living with HIV

Patient Preference and Adherence
Ana Codonal,1,2 Alicia Lázaro,2,3,* Elena Martínez,4,* Alberto Delgado,4,* Miguel Torralba2,4,5,*1Pharmacy Department, Santos Reyes Hospital, Aranda de Duero, Spain; 2University of Alcalá, Alcalá de Henares, Spain ...
Codonal A, Lázaro A, Martínez E, Delgado A, Torralba M   +4 more
doaj  

Ultrasound for the determination of appropriate needle length for intragluteal injection of long-acting rilpivirine-cabotegravir. [PDF]

HIV Med
Gueuning C, Brizmohun M, Dauby N, Martin C.   +3 more
europepmc   +1 more source

Beyond Efficacy: The Access, Delivery Systems, Acceptability, Persistence, and Transition Management “ADAPT” Framework for Long-Acting Injectable PrEP in Sub-Saharan Africa

HIV/AIDS: Research and Palliative Care
Eric Nzirakaindi Ikoona,1 Lucy Namulemo,2 Ronald Kaluya,3 Rebecca Ikoona,4 Foday Sahr51Department of Evaluation and Research, National Public Health Agency, Freetown, Sierra Leone; 2Department of Treatment Services, Foothills Community-Based ...
Ikoona EN, Namulemo L, Kaluya R, Ikoona R, Sahr F   +4 more
doaj  

Brief Report: Real-World Uptake and Clinical Outcomes of Long-Acting Injectable Cabotegravir/Rilpivirine in the United States, 2021-2023. [PDF]

J Acquir Immune Defic Syndr
O'Shea J, Derton A, Henson J, Iqbal K, Briggs-Hagen M, Kourtis AP, Buchacz K.   +6 more
europepmc   +1 more source

HIV-1 Sub-subtype A6 Remains Susceptible to Second-Generation Integrase Inhibitors With Limited Emergence of Resistance in Vitro. [PDF]

Open Forum Infect Dis
Saladini F, Giannini A, Giammarino F, Antonova A, Ozhmegova E, Kaiser R, Dragoni F, Boccuto A, Vicenti I, Sönnerborg A, Bobkova M, Zazzi M.   +11 more
europepmc   +1 more source

Long-Acting Injectable Cabotegravir HIV PrEP Uptake, Adherence, and Persistence in Two Large US Integrated Healthcare Systems. [PDF]

J Acquir Immune Defic Syndr
Traeger MW, Traeger MW, Leyden WA, Eberhart LG, Volk JE, Silverberg MJ, Horberg MA, Davis TL, Mayer KH, Krakower DS, Young JG, Jenness SM, Marcus JL.   +12 more
europepmc   +1 more source

Long-acting cabotegravir for prevention: hope versus reality [PDF]

The Lancet HIV, 2017
McCormack, S, Boffito, M
openaire   +3 more sources

Impact of implementation process on long-acting cabotegravir/rilpivirine prescription at 9 HIV clinics, 2021-2024. [PDF]

J Acquir Immune Defic Syndr
Lujintanon S, Lesko CR, Haw NJL, Hickey MD, Zalla LC, Kilcrease C, Grochowski J, Hill LA, Cachay ER, Budak JZ, Crane HM, Fleming J, Mayer KH, Rutstein SE, Turner B, Nevin C, Burkholder GA, Wang N, Yendewa GA, Moss R, Pettit A, Rodriguez AE, Johnson MO, Christopoulos KA.   +23 more
europepmc   +1 more source

Authors’ response: Addressing the blind spot of self-reported adherence in the era of long-acting PrEP

Eurosurveillance
on behalf of the authors of the original article
doaj   +1 more source